Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral antiplatelet medication that belongs to the P2Y12 inhibitor class. It reversibly binds to the P2Y12 receptor on platelets, preventing adenosine diphosphate (ADP)-mediated platelet activation and aggregation.
## Primary Indications
* Reduction of thrombotic cardiovascular events (including myocardial infarction and stroke) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
* In combination with aspirin, for the prevention of stent thrombosis in patients treated with coronary stent placement.
## Adult Dosing
* **Acute Coronary Syndrome (ACS):**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* Continue for at least 12 months, or as per local guidelines and clinical assessment. Longer durations may be considered for select patients.
* **History of Myocardial Infarction (MI) (at least 1 year after ACS or MI):**
* **Maintenance Dose:** 60 mg orally twice daily.
* This is for patients who have had an MI at least 1 year prior and are currently receiving or have previously received treatment for ACS.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor. Its use in pediatric populations is not recommended.
## Dose Adjustments
* **Hepatic Impairment:**
* **Severe Hepatic Impairment:** Use with caution; no dose adjustment recommended, but clinical monitoring is advised due to potential for increased exposure.
* **Mild to Moderate Hepatic Impairment:** No dose adjustment is needed.
* **Renal Impairment:** No dose adjustment is needed.
## Contraindications
* Hypersensitivity to ticagrelor or any excipients.
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
## Adverse Effects
The most significant adverse effect is bleeding, including life-threatening and fatal bleeding. Other common adverse effects include:
* Dyspnea (shortness of breath)
* Bradycardia
* Increased serum creatinine
* Ventricular pauses
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, ritonavir):** May increase ticagrelor exposure. Use with caution and consider dose reduction if indicated.
* **Strong CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine):** May decrease ticagrelor exposure. Avoid concomitant use.
* **Other Antithrombotics (e.g., warfarin, other antiplatelets, NSAIDs):** Increased risk of bleeding. Use with caution and monitor closely for signs of bleeding.
* **Statins:** Ticagrelor can increase statin concentrations (particularly simvastatin and atorvastatin) by inhibiting OATP1B1/3. Dose adjustments of statins may be necessary.
* **Digoxin:** Ticagrelor can increase digoxin concentrations. Monitor digoxin levels and for signs of toxicity.
## Monitoring
* **Bleeding:** Closely monitor for any signs or symptoms of bleeding (e.g., hematuria, melena, bruising, epistaxis, gingival bleeding).
* **Cardiac Rhythm:** Monitor for bradycardia, especially in patients with predisposing factors.
* **Renal Function:** Monitor serum creatinine.
* **Serum Uric Acid:** Ticagrelor can increase uric acid levels.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning its effect can be reversed more quickly than clopidogrel if urgent surgery is required.
* Dyspnea is a common side effect and usually does not require discontinuation of the drug, but it's important to rule out other causes.
* Ticagrelor should be taken twice daily, with or without food.
* Patients should be advised to inform all healthcare providers that they are taking ticagrelor.
* Discontinuation of ticagrelor, especially prematurely, increases the risk of stent thrombosis, MI, and death.
***
**Disclaimer:** This information is intended for educational purposes and does not substitute for professional medical advice. Always consult the current prescribing information and your healthcare provider for accurate and up-to-date guidance on medication use.
